Koers M Pharmaceutical Inc Canadian Securities Exchange
Aandelen
CA55346E2050
Biotechnologie & Medisch Onderzoek
Omzet 2018 | 0,75 1,03 0,7 | Omzet 2019 | 0,71 0,97 0,66 | Marktkapitalisatie | 3,53 mln. 4,84 mln. 3,28 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2018 | -5 mln. -6,87 mln. -4,65 mln. | Nettowinst (verlies) 2019 | -1 mln. -1,37 mln. -930K | EV/omzet 2018 | 4.852.616 x |
Nettoschuld 2018 | 319K 438K 297K | Nettoschuld 2019 | 848K 1,16 mln. 788K | EV/omzet 2019 | 6.168.166 x |
K/w-verhouding 2018 |
-0,6
x | K/w-verhouding 2019 |
-1,97
x | Werknemers | - |
Dividendrendement 2018 * |
-
| Dividendrendement 2019 |
-
| Vrij verhandelbaar | 72,04% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | - | 03-01-18 | |
Robert Payment
DFI | Director of Finance/CFO | 42 | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Donald Skeith
BRD | Director/Board Member | 69 | 01-12-14 |
William Rodgers
BRD | Director/Board Member | - | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+21,74% | 46,81 mld. | |
-0,97% | 41,37 mld. | |
+47,07% | 41,29 mld. | |
-3,52% | 28,87 mld. | |
+11,12% | 26,06 mld. | |
-19,37% | 19,13 mld. | |
+31,18% | 12,39 mld. | |
-0,04% | 12,08 mld. | |
+0,39% | 11,96 mld. |